No significant differences in the frequencies of PD1- or CTLA4-expressing CD33+ (AML blast-containing) cells between patients with adverse vs. good ELN risk or patients who achieved or did not achieve complete remission after induction therapy were seen. The gene discussed is CD33; the disease is acute myeloid leukemia.